Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rate, Phase 3 Data Show

Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rate, Phase 3 Data Show

Хемофилия новини днес

Изображение

Please enable the javascript to submit this form

Подкрепено от образователни субсидии от Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics и uniQure, Inc.

Основен SSL